Research programme: coronavirus and infectious disease therapeutics - Mannin Research/Q BioMed
Latest Information Update: 28 Mar 2024
At a glance
- Originator Mannin Research
- Class Anti-infectives; Antivirals; Small molecules
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in Canada
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
- 28 Mar 2024 No recent reports of development identified for research development in Infections in Canada
Development Overview
Introduction
Small molecules targeted against COVID-2019 infections (originated in Wuhan, China) and other infectious diseases [Infections in development table], are being jointly developed by Q BioMed and Mannin Research. The development is utilising the Mannin's Tie2 based small molecule platform that addresses vascular leakage, and Cyclica's proprietary AI-augmented drug discovery platform, Ligand Design and Ligand Express. The development targets the activation of the Angiopoietin-Tie2 signaling pathway. The therapeutics will constitute a potential adjunct treatment against coronavirus. The collaborative endeavor seeks to augment the survival rate of patients by lowering endothelial dysfunction and severity of infectious diseases, facilitated by an enhancement of host-directed therapeutic response. Early research is underway in the US and Canada.
As at March 2024, no recent reports of development had been identified for research development in COVID-2019-infections in USA, Canada, research development in Infections in Canada, USA.
Company Agreements
In March 2019, Q BioMEd amended the patent and technology license and purchase option agreement that the company had initially entered into with Mannin Research. Under the amendment, the term of the option granted under the Mannin Agreement was extended to October 29, 2021. Earlier, in October 2015, Q BioMed entered into a patent and technology license and purchase option agreement with Mannin Research, whereby Q BioMed was granted a worldwide, exclusive license on, and option to acquire, certain Mannin intellectual property, or IP, within a four-year term. The Mannin IP was initially focused on developing a first-in-class eye drop treatment for glaucoma. The technology platform may be expanded in scope beyond ophthalmological uses and may include cystic kidney disease, cardiovascular diseases and infectious disease. This platform technology has application in many disease states that result in leaky vessels and the inefficient flow of fluids, including COVID-2019 infections. [1] [2]
In April 2020, Mannin entered into a joint venture agreement with Cyclica to develop drugs for COVID-19 and other viral infections. The accelerated development is the result of a joint venture (JV) between Mannin, with its Tie2 based small molecule platform that addresses vascular leakage, and Cyclica, with its proprietary AI-augmented drug discovery platform, Ligand Design and Ligand Express. The JV agreement will deploy Cyclica’s unique AI platform to accelerate the development of new treatments based on Mannin’s Tie2 based platform. [3]
Key Development Milestones
As at February 2020, early research for the treatment of COVID-2019 infections and other infections, is underway in the US and Canada [4] .
Financing information
In April 2020, Q BioMed entered into a financial restructuring and received additional $US4 000 000. The company intends to use this funding to advance pipeline assets including a potential treatment for COVID-19, influenza and others, liver cancer therapy Uttroside B and rare disease drug development in non-verbal autism spectrum disorders [5] .
In February 2020, Q BioMed reported the submission of a funding application by Mannin, to the Small Business Technology Transfer Grant administered by the U.S. National Institutes of Health, for the investigation of specific applications of Mannin's therapeutic platform [4] .
In September 2019, Mannin became the recipient of a grant totaling approximately $US7.7 million, awarded by the German state of Saxony. The grant is intended for the advancement of Mannin's novel therapeutics, responsible for lowering endothelial dysfunction and loss of endothelial barrier integrity, implicated in viral and bacterial infections, leading to acute and severe lung injury [4] .
Drug Properties & Chemical Synopsis
- Formulation unspecified
- Class Anti-infectives, Antivirals, Small molecules
- Target TIE-2 receptor
- Mechanism of Action TIE-2 receptor agonists
-
WHO ATC code
J (Anti-infectives For Systemic Use)
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J (General Anti-Infectives Systemic)
J5 (Antivirals for Systemic Use)
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | - | No development reported (Research) | Canada, USA | unspecified / unspecified | Mannin Research | 28 Mar 2024 |
| Infections | - | - | No development reported (Research) | Canada, USA | unspecified / unspecified | Mannin Research | 28 Mar 2024 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| Mannin Research | Originator | Canada |
| Mannin Research | Owner | Canada |
| Q BioMed | Licensee | USA |
| Cyclica | Collaborator | Canada |
Future Events
| Expected Date | Event Type | Description | Updated |
|---|---|---|---|
| 31 Dec 2020 | Trial Update | Q BioMed and Mannin plans clinical trials for COVID-2019 infections in 2020 [3] | 27 Apr 2020 |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in Canada Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in COVID-2019-infections in USA Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in Infections in Canada Updated 28 Mar 2024 |
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for research development in Infections in USA Updated 28 Mar 2024 |
| 22 Apr 2020 | Trial Update | Q BioMed and Mannin plans clinical trials for COVID-2019 infections in 2020 [3] Updated 27 Apr 2020 |
| 04 Feb 2020 | Phase Change | Early research in COVID-2019-infections in Canada (unspecified route) [4] Updated 06 Feb 2020 |
| 04 Feb 2020 | Phase Change | Early research in COVID-2019-infections in USA (unspecified route) [4] Updated 06 Feb 2020 |
| 04 Feb 2020 | Phase Change | Early research in Infections in Canada (unspecified route) [4] Updated 06 Feb 2020 |
| 04 Feb 2020 | Phase Change | Early research in Infections in USA (unspecified route) [4] Updated 06 Feb 2020 |
| 26 Mar 2019 | Licensing Status | Q BioMEd amends the patent and technology license and purchase option agreement with Mannin Research for Mannin platform [1] [2] Updated 20 Aug 2020 |
| 29 Oct 2015 | Licensing Status | Q BioMed in-licenses Manin platform from Mannin Research [1] [2] Updated 20 Aug 2020 |
References
-
Q BioMed Quarterly report, Form 10-Q, July 2020. Internet-Doc 2020;.
Available from: URL: https://www.sec.gov/Archives/edgar/data/1596062/000110465920083773/tm2024749-1_10q.htm -
Q BioMed SEC filining Form-S1 April 2020. Internet-Doc 2020;.
Available from: URL: https://qbiomed.com/investors/filings -
Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics.
Media Release -
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases.
Media Release -
Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG